Slingshot members are tracking this event:
FDAA approves Merck & co. (MRK) product KEYTRUDA® (pembrolizumab) for the treatment of non-squamous non-small cell lung cance (NSCLC)
Slingshot Insights Explained
May 10, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Non-squamous Non-small Cell Lung Cance, Nsclc, Keytruda, Pembrolizumab